ProPhase LabsPRPH -2.19% Return-on-Tangible-Equity is 0.00% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 193 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 518134.2% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. ProPhase Labs's annualized net income for the quarter that ended in Dec. 2025 was $-29.59 Mil. ProPhase Labs's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $-6.27 Mil. Therefore, ProPhase Labs's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was N/A%.
The historical rank and industry rank for ProPhase Labs's Return-on-Tangible-Equity or its related term are showing as below:
During the past 13 years, ProPhase Labs's highest Return-on-Tangible-Equity was 214.71%. The lowest was -441.19%. And the median was -21.63%.
PRPH's Return-on-Tangible-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.07 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
ProPhase Labs Return-on-Tangible-Equity Related Terms
ProPhase Labs Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPH vs IDTA, IVRO, FUNI: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
ProPhase Labs (PRPH) has a Return-on-Tangible-Equity of 0.00% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ProPhase Labs and its competitors. According to the industry distribution chart, ProPhase Labs ranks #999999 out of 193 companies in the Medical Diagnostics & Research industry.
Is ProPhase Labs' Return-on-Tangible-Equity too high?
ProPhase Labs' current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, ProPhase Labs ranks #999999 out of 193 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' Return-on-Tangible-Equity compare to IDTA and IVRO?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #999999 out of 193 companies for Return-on-Tangible-Equity. This places ProPhase Labs in the lower half of its industry. The industry median Return-on-Tangible-Equity is 0.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.07, based on 193 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.09 — trading 85.8% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Return-on-Tangible-Equity is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 